TR200100859T2 - Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi - Google Patents

Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi

Info

Publication number
TR200100859T2
TR200100859T2 TR2001/00859T TR200100859T TR200100859T2 TR 200100859 T2 TR200100859 T2 TR 200100859T2 TR 2001/00859 T TR2001/00859 T TR 2001/00859T TR 200100859 T TR200100859 T TR 200100859T TR 200100859 T2 TR200100859 T2 TR 200100859T2
Authority
TR
Turkey
Prior art keywords
capecitabine
gemcitabine
acetildinal
cancer chemotherapy
cisplatin combination
Prior art date
Application number
TR2001/00859T
Other languages
English (en)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200100859T2 publication Critical patent/TR200100859T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Acetyldinaline'in, gemsitabin, farmasötik olarak kabul edilebilir bir tuzu, kapesitabin veya cisplatin ile kombinasyon halinde, kanser tedavisinde sinerjistik bir etkisi vardir.
TR2001/00859T 1998-09-25 1999-07-08 Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi TR200100859T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
TR200100859T2 true TR200100859T2 (tr) 2001-08-21

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00859T TR200100859T2 (tr) 1998-09-25 1999-07-08 Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi

Country Status (34)

Country Link
US (3) US6469058B1 (tr)
EP (1) EP1115391B1 (tr)
JP (1) JP2002525320A (tr)
KR (1) KR20010075348A (tr)
CN (1) CN1319009A (tr)
AP (1) AP2001002109A0 (tr)
AT (1) ATE225655T1 (tr)
AU (1) AU762079B2 (tr)
BG (1) BG105470A (tr)
BR (1) BR9913952A (tr)
CA (1) CA2342981A1 (tr)
CZ (1) CZ2001905A3 (tr)
DE (1) DE69903458T2 (tr)
DK (1) DK1115391T3 (tr)
EA (1) EA200100369A1 (tr)
EE (1) EE200100187A (tr)
ES (1) ES2185378T3 (tr)
GE (1) GEP20043199B (tr)
HK (1) HK1040190A1 (tr)
HR (1) HRP20010225B1 (tr)
HU (1) HUP0103640A3 (tr)
ID (1) ID30046A (tr)
IL (1) IL141951A0 (tr)
IS (1) IS5888A (tr)
NO (1) NO20011493L (tr)
NZ (1) NZ510504A (tr)
OA (1) OA11659A (tr)
PL (1) PL348673A1 (tr)
PT (1) PT1115391E (tr)
SK (1) SK3602001A3 (tr)
TR (1) TR200100859T2 (tr)
WO (1) WO2000018393A1 (tr)
YU (1) YU22401A (tr)
ZA (1) ZA200102233B (tr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
KR100892016B1 (ko) * 2002-03-04 2009-04-07 슬로안-케테링인스티튜트퍼캔서리서치 말단 분화의 유도 방법
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US7839972B2 (en) 2005-07-22 2010-11-23 Tomotherapy Incorporated System and method of evaluating dose delivered by a radiation therapy system
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
WO2007014106A2 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
US7773788B2 (en) * 2005-07-22 2010-08-10 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
JP2009502257A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド デリバーされた線量を評価するための方法およびシステム
CN101267768A (zh) 2005-07-22 2008-09-17 断层放疗公司 对接受放射疗法的患者的呼吸时相进行检测的系统和方法
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
WO2008027839A1 (en) * 2006-08-31 2008-03-06 Spectrum Pharmaceuticals, Inc. Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists
WO2009096245A1 (ja) * 2008-01-28 2009-08-06 Nanocarrier Co., Ltd. 医薬組成物又は組合せ剤
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
JP5687687B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
CN105027227B (zh) 2013-02-26 2017-09-08 安科锐公司 电磁致动的多叶准直器
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (en) * 1997-04-24 1998-10-29 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Also Published As

Publication number Publication date
ES2185378T3 (es) 2003-04-16
KR20010075348A (ko) 2001-08-09
NO20011493D0 (no) 2001-03-23
AP2001002109A0 (en) 2001-03-31
DK1115391T3 (da) 2003-02-10
EE200100187A (et) 2002-08-15
EP1115391A1 (en) 2001-07-18
OA11659A (en) 2004-12-08
CN1319009A (zh) 2001-10-24
JP2002525320A (ja) 2002-08-13
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
CA2342981A1 (en) 2000-04-06
PL348673A1 (en) 2002-06-03
EP1115391B1 (en) 2002-10-09
SK3602001A3 (en) 2002-07-02
BR9913952A (pt) 2001-06-12
BG105470A (en) 2001-12-29
GEP20043199B (en) 2004-03-25
US6469058B1 (en) 2002-10-22
WO2000018393A1 (en) 2000-04-06
AU5092199A (en) 2000-04-17
DE69903458D1 (de) 2002-11-14
ID30046A (id) 2001-11-01
HUP0103640A2 (en) 2002-06-29
NO20011493L (no) 2001-05-23
ATE225655T1 (de) 2002-10-15
US20030170300A1 (en) 2003-09-11
HRP20010225A2 (en) 2002-04-30
IS5888A (is) 2001-03-14
PT1115391E (pt) 2003-02-28
YU22401A (sh) 2004-03-12
DE69903458T2 (de) 2003-07-10
ZA200102233B (en) 2002-06-18
CZ2001905A3 (cs) 2001-08-15
HK1040190A1 (zh) 2002-05-31
US20030086965A1 (en) 2003-05-08
EA200100369A1 (ru) 2001-10-22
HRP20010225B1 (en) 2004-10-31
NZ510504A (en) 2003-09-26
AU762079B2 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
TR200100859T2 (tr) Asetildinalin ve gemsitabin, kapesitabin veya cisplatin kombinasyonu ile kanser kemoterapisi
BR0207378A (pt) Tratamento de câncer
DE60022367D1 (de) Bandscheibenprothese mit zähnen auf den seiten
NZ508249A (en) Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C
MY133016A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
DE59200763D1 (de) Zange mit wahlweiser frontaler und seitlicher Einführung.
ES2180791T3 (es) Juego de construccion destinado principalmente a la creacion de pistas de rodaje.
TR199800644T2 (tr) Bir apoptoz inhibitörü olarak y-RAR antagonist ligandi ya da alfa-RAR antagonist ligandi.
ZA200005161B (en) Anti-inflammatory, antibacterial benzyl phenol agents.
UY26431A1 (es) Quimioterapia de combinación
FI934565A (fi) Pyrimidinderivat foer att oeka antitumoeraktiviteten
DK0980205T3 (da) Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
HUP0402401A2 (hu) Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
EA200000025A1 (ru) 13-дигидро-3'-азиридиноантрациклины
AU8497201A (en) Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
ES1041505Y (es) Abrazadera de union y sujecion oculta, aplicable en lamas de madera para la configuracion de tarimas y similares.
TR200002469T2 (tr) İkameli 1,2,4-triazol [3,4-a]piridazin.
ES1043499U (es) Tapa-soporte perfeccionada.
RU97102875A (ru) Способ лечения хронического гастрита с пониженной секрецией
DE29812269U1 (de) Terminplaner mit Stempel und Taschenrechner
ES1038165U (es) Funda spu "torre" de apertura frontal mediante cremalleras.
ECSP003755A (es) Quimioterapia de combinacion
MX9703460A (es) Composicion de cisplatino en combinacion con 2,2'ditio-bis (etanosulfonato) (dimesna).